Inventor · disambiguated record
Mark Pickworth
Also filed as: PICKWORTH MARK
39 granted patents·7 pending applications·376 citations·filing 2013–2024
98Inventor score
Files withHEPTARES THERAPEUTICS LTD39NXERA PHARMA UK LTD5BROWN GILES ALBERT1OREXIA THERAPEUTICS LTD1
Top patents by PatentIndex Score
46 records- 0198US11254656B2Muscarinic agonistsHEPTARES THERAPEUTICS LTD·Filed 2020·Granted Feb 22, 2022·10 cites·10 claims
- 0298US11014880B2Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2020·Granted May 25, 2021·9 cites·13 claims
- 0398US10961225B2Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptorHEPTARES THERAPEUTICS LTD·Filed 2020·Granted Mar 30, 2021·11 cites·16 claims
- 0498US9670183B2Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2015·Granted Jun 6, 2017·34 cites·23 claims
- 0597US11834407B2Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2021·Granted Dec 5, 2023·5 cites·13 claims
- 0697US10689368B2Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptorHEPTARES THERAPEUTICS LTD·Filed 2019·Granted Jun 23, 2020·12 cites·20 claims
- 0797US10196380B2Bicyclic aza compounds as muscarinic M1 receptor and/or M4 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2018·Granted Feb 5, 2019·20 cites·16 claims
- 0896US11091456B2Muscarinic agonistsHEPTARES THERAPEUTICS LTD·Filed 2019·Granted Aug 17, 2021·10 cites·20 claims
- 0996US11034704B2Muscarinic receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2019·Granted Jun 15, 2021·10 cites·13 claims
- 1096US10759751B2Substituted spirocyclohexanes as muscarinic M1 receptor and/or M4 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2019·Granted Sep 1, 2020·12 cites·18 claims
- 1196US10259787B2Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2017·Granted Apr 16, 2019·13 cites·8 claims
- 1296US9926297B2Bicyclic AZA compounds as muscarinic M1 receptor and/or M4 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2017·Granted Mar 27, 2018·19 cites·18 claims
- 1396US9758506B2Muscarinic agonistsHEPTARES THERAPEUTICS LTD·Filed 2016·Granted Sep 12, 2017·22 cites·20 claims
- 1495US10548884B2Muscarinic agonistsHEPTARES THERAPEUTICS LTD·Filed 2016·Granted Feb 4, 2020·11 cites·17 claims
- 1595US10385039B2Bicyclic aza compounds as muscarnic M1 receptor and/or M4 receptor antagonistsHEPTARES THERAPEUTICS LTD·Filed 2018·Granted Aug 20, 2019·13 cites·20 claims
- 1694US12024499B2Muscarinic agonistsHEPTARES THERAPEUTICS LTD·Filed 2022·Granted Jul 2, 2024·2 cites·7 claims
- 1794US10030035B2Muscarinic receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2015·Granted Jul 24, 2018·14 cites·17 claims
- 1894US9669013B2Bicyclic aza compounds as muscarinic M1 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2016·Granted Jun 6, 2017·14 cites·18 claims
- 1994US9266857B2Bicyclic AZA compounds as muscarinic M1 receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2013·Granted Feb 23, 2016·23 cites·14 claims
- 2093US10738029B2Muscarinic agonistsHEPTARES THERAPEUTICS LTD·Filed 2016·Granted Aug 11, 2020·12 cites·6 claims
- 2193US10428088B2Muscarinic receptor agonistsHEPTARES THERAPEUTICS LTD·Filed 2018·Granted Oct 1, 2019·11 cites·10 claims
- 2293US10351545B2Muscarinic agonistsHEPTARES THERAPEUTICS LTD·Filed 2017·Granted Jul 16, 2019·10 cites·30 claims
- 2393US10167272B2Muscarinic agonistsHEPTARES THERAPEUTICS LTD·Filed 2018·Granted Jan 1, 2019·11 cites·21 claims
- 2493US9975890B2Bicyclic AZA compounds as muscarinic M1 receptor antagonistsHEPTARES THERAPEUTICS LTD·Filed 2017·Granted May 22, 2018·10 cites·9 claims
- 2592US10259802B2Bicyclic aza compounds as muscarinic M1 receptor antagonistsHEPTARES THERAPEUTICS LTD·Filed 2018·Granted Apr 16, 2019·9 cites·20 claims
- 2691US11324738B2Muscarinic agonistsHEPTARES THERAPEUTICS LTD·Filed 2019·Granted May 10, 2022·9 cites·18 claims
- 2791US10167284B2Spirocyclic compounds as agonists of the muscarinic M1 receptor and/or M4 receptorHEPTARES THERAPEUTICS LTD·Filed 2016·Granted Jan 1, 2019·12 cites·20 claims
- 2889US10166226B2CGRP receptor antagonistsHEPTARES THERAPEUTICS LTD·Filed 2018·Granted Jan 1, 2019·3 cites·16 claims
- 2989US9925178B2CGRP receptor antagonistsHEPTARES THERAPEUTICS LTD·Filed 2017·Granted Mar 27, 2018·4 cites·16 claims
- 3088US9808457B2CGRP receptor antagonistsHEPTARES THERAPEUTICS LTD·Filed 2016·Granted Nov 7, 2017·6 cites·17 claims
- 3186US9688660B2CGRP receptor antagonistsHEPTARES THERAPEUTICS LTD·Filed 2016·Granted Jun 27, 2017·5 cites·13 claims
- 3284US9802935B2CGRP receptor antagonistsHEPTARES THERAPEUTICS LTD·Filed 2016·Granted Oct 31, 2017·4 cites·9 claims
- 3381US10888561B2CGRP receptor antagonistsHEPTARES THERAPEUTICS LTD·Filed 2019·Granted Jan 12, 2021·2 cites·10 claims
- 3480US10300056B2CGRP receptor antagonistsHEPTARES THERAPEUTICS LTD·Filed 2017·Granted May 28, 2019·2 cites·19 claims
- 3578US10259812B2CGRP receptor antagonistsHEPTARES THERAPEUTICS LTD·Filed 2017·Granted Apr 16, 2019·2 cites·11 claims
- 3677US12202843B2Muscarinic receptor agonistsNXERA PHARMA UK LTD·Filed 2021·Granted Jan 21, 2025·0 cites·18 claims
- 3775US2025115587A1Pyrazole derivatives as h4 antagonist compoundsBROWN GILES ALBERT·Filed 2024·Application pending·0 cites
- 3872US12178813B2CGRP receptor antagonistsNXERA PHARMA UK LTD·Filed 2020·Granted Dec 31, 2024·0 cites·22 claims
- 3966US12234227B2Pyrazole derivatives as H4 antagonist compoundsNXERA PHARMA UK LTD·Filed 2019·Granted Feb 25, 2025·0 cites·17 claims
- 4059US12215099B2Quinolinone and benzoxazine derivatives as muscarinic M1 and/or M4 receptor agonistsNXERA PHARMA UK LTD·Filed 2019·Granted Feb 4, 2025·0 cites·11 claims
- 4159US2024217930A1Sars-cov-2 mpro inhibitor compoundsHEPTARES THERAPEUTICS LTD·Filed 2022·Application pending·0 cites
- 4258US2024083845A1Sars-cov-2 mpro inhibitor compoundsHEPTARES THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 4357US2024317775A1H4 Antagonist CompoundsHEPTARES THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 4455US2023331720A1Medium- or macro-cyclic benzyl-substituted heterocycle derivatives and their uses as orexin-2 receptor agonistsOREXIA THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 4555US2025340531A1Crystalline forms and salts of a muscarinic receptor agonistNXERA PHARMA UK LTD·Filed 2023·Application pending·0 cites
- 4654US2023167094A1H4 antagonist compoundsHEPTARES THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Mark Pickworth files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →